Difference between revisions of "CTSC:education library"
From NAMIC Wiki
(4 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
− | Back to [[ | + | Back to [[CTSC:education|Harvard Catalyst Imaging Working Group Education]] <br> |
==DCE-MRI== | ==DCE-MRI== | ||
− | * Dynamic contrast enhanced MRI in prostate cancer, Eur. J. Radiol. 2007, 63 (3), 328-334 | + | * Dynamic contrast enhanced MRI in prostate cancer, R. Alonzi, Eur. J. Radiol. 2007, 63 (3), 328-334 |
'''doi''':10.1016/j.ejrad.2007.06.028 | '''doi''':10.1016/j.ejrad.2007.06.028 | ||
− | == | + | ==Biomarkers== |
+ | |||
+ | * Surrogate Endpoints And FDA’s Accelerated Approval Process, Thomas R. Fleming, Heath Affairs, 2005, 24 (1) 67-78 | ||
+ | '''doi''': 10.1377/hlthaff.24.1.67 | ||
+ | |||
+ | == Tumor response == | ||
− | + | * New Guidelines to Evaluate the Response to Treatment in Solid Tumors, P. Therasse, Journal of the National Cancer Institute, 2000, 92 (3), 205-216 | |
+ | * Measurement of Clinical and Subclinical Tumour Response Using [18F]-Fuorodeoxyglucose and Positron Emission Tomography: Review and 1999 EORTC Recommendations, H. Young, European Journal of Cancer, 1999, 35 (13), 1773-1782 |
Latest revision as of 19:57, 28 October 2010
Home < CTSC:education libraryBack to Harvard Catalyst Imaging Working Group Education
DCE-MRI
- Dynamic contrast enhanced MRI in prostate cancer, R. Alonzi, Eur. J. Radiol. 2007, 63 (3), 328-334
doi:10.1016/j.ejrad.2007.06.028
Biomarkers
- Surrogate Endpoints And FDA’s Accelerated Approval Process, Thomas R. Fleming, Heath Affairs, 2005, 24 (1) 67-78
doi: 10.1377/hlthaff.24.1.67
Tumor response
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors, P. Therasse, Journal of the National Cancer Institute, 2000, 92 (3), 205-216
- Measurement of Clinical and Subclinical Tumour Response Using [18F]-Fuorodeoxyglucose and Positron Emission Tomography: Review and 1999 EORTC Recommendations, H. Young, European Journal of Cancer, 1999, 35 (13), 1773-1782